Heterobifunctional Compounds Targeting Androgen Receptor and BRD4
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are not effective for all patients and often have substantial adverse side effects, highlighting the need for new therapies that achieve an anti-cancer effect through a different mechanism.
Innovation Solution
Development of heterobifunctional compounds that can bind to both the androgen receptor and BRD4 protein, potentially disrupting cancer cell growth and survival pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer therapies are used, then anti-cancer effect is achieved, but substantial adverse side effects occur
Solution Approach 1:
The therapeutic agent is segmented into two distinct functional moieties: a first moiety that binds to the androgen receptor and a second moiety that binds to BRD4. This segmentation allows each moiety to independently target its specific biological target, achieving anti-cancer effects through dual binding while potentially reducing off-target adverse effects associated with conventional single-mechanism therapies
Solution Approach 2:
The therapeutic agent is designed with multi-functionality by incorporating both androgen receptor binding capability and BRD4 binding capability within a single molecule. This heterobifunctional design enables the agent to simultaneously engage two different biological targets, providing a unified therapeutic approach that addresses cancer through multiple mechanisms while potentially improving the therapeutic index
2Reliability
If current cancer therapies are used, then cancer treatment is provided, but treatment effectiveness varies across patients
Solution Approach 1:
The heterobifunctional therapeutic agent combines androgen receptor binding and BRD4 binding in a single molecule, creating a multi-functional agent that can potentially overcome resistance mechanisms that affect conventional single-target therapies. This dual-mechanism approach may provide more consistent effectiveness across different patient populations by engaging multiple parallel pathways
3Adaptability or versatility
If heterobifunctional compounds are developed, then new anti-cancer mechanism is achieved, but compound complexity increases
Solution Approach 1:
The patent employs linker moieties as intermediaries that connect the androgen receptor-binding moiety and the BRD4-binding moiety. These linkers serve as structural bridges that enable the heterobifunctional agent to achieve its dual-target capability while providing a modular framework that can be systematically optimized to balance functionality with synthetic feasibility and pharmacokinetic properties
Data Source
AI summary
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use treating disease, such as cancer.